Trial results for a study investigating the Decision-Making Education for Choices in Diabetes Every Day (DECIDE) program for African American patients with Type 2 Diabetes were posted on ClinicalTrials.gov on 2026-03-20, indicating a median HbA1c difference of -0.4% between the eDECIDE web-based and traditional groups at follow-up.
Background
Type 2 Diabetes is a chronic metabolic condition characterized by high blood sugar levels, often requiring careful self-management, including diet, exercise, and medication adherence. For many patients, particularly those from specific demographic groups, educational programs that foster problem-solving skills can be crucial for managing the daily challenges of living with diabetes. The Decision-Making Education for Choices in Diabetes Every Day (DECIDE) program is a curriculum designed to support patients in this regard. This study aimed to conduct an in-depth review of the DECIDE curriculum, comparing a web-based delivery method (eDECIDE) with the traditional face-to-face group setting.
Trial design
This completed study, designated as Phase NA, enrolled 36 participants with Diabetes Mellitus, Type 2. The trial's primary purpose was to complete an in-depth review of the DECIDE curriculum using a task analysis process, with findings intended to develop a web-based version. Participants were assigned to either the eDECIDE Web-based Intervention Group or the DECIDE Traditional Group, which served as an active comparator. The study examined various outcomes related to glycemic control, health problem-solving, and self-care behaviors.
Key results
The trial reported several key measurements at baseline and 18-week follow-up:
- Percentage of Glycated Hemoglobin (HbA1c) (units: Percentage of glycated hemoglobin):
- eDECIDE Web-based Intervention Group: Median 8.0 at baseline and 8.40 at 18-week follow-up.
- DECIDE Traditional Group: Median 7.40 at baseline and 7.35 at 18-week follow-up.
- Health Problem Solving Scores Outcomes (units: score on a scale):
- eDECIDE Web-based Intervention Group/Arm: Median 22.54 at baseline and 22.96 at 18-week follow-up.
- Active Comparator: DECIDE Traditional Group: Median 17.9 at baseline and 24.02 at 18-week follow-up.
- Diabetes Self-Care Behaviors - Monitoring Blood Glucose Levels (units: Participants):
- eDECIDE Web-based Intervention Group/Arm: 7 participants at baseline and 5 participants at 18-week follow-up.
- Active Comparator: DECIDE Traditional Group: 6 participants at baseline and 3 participants at 18-week follow-up.
Statistical analyses comparing the two groups for final values included:
- A Wilcoxon (Mann-Whitney) analysis for the mean difference in HbA1c final values showed a mean difference of -1.04 (95.0% CI: -5.487 to 3.41), with a p-value of 0.9.
- Another Wilcoxon (Mann-Whitney) analysis for the median difference in HbA1c final values showed a median difference of -0.4 (95.0% CI: -5.48 to 3.41), with a p-value of 0.6734. The study was originally powered at 80% to detect a change in HbA1c level of at least 1% between the two groups.
What this means
The posted results provide detailed measurements from a task analysis study comparing web-based and traditional delivery methods of the DECIDE problem-solving curriculum for Type 2 Diabetes patients. While both groups showed varying changes in HbA1c, health problem-solving scores, and self-care behaviors, the statistical analyses indicated no significant difference between the eDECIDE web-based intervention and the traditional DECIDE group for the final HbA1c values, with p-values of 0.9 for mean difference and 0.6734 for median difference. Given the small enrollment of 36 participants, these findings contribute to the understanding of the curriculum's implementation but do not suggest a clear superiority of one delivery method over the other based on these specific outcome measures.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT03855449, titled "A Task Analysis Study of DECIDE For African American Patients With Type 2 Diabetes", were posted on 2026-03-20 on clinicaltrials.gov.